Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering Cancer Center, Sidney Kimmel Center
mi
from
New York, NY
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering Cancer Center, Sidney Kimmel Center
mi
from
New York, NY
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Department of Medicine MSG @ SUNY HSC @ Syrcacuse, Inc.
mi
from
Oneida, NY
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Department of Medicine MSG @ SUNY HSC @ Syrcacuse, Inc.
mi
from
Oneida, NY
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Department of Medicine MSG at SUNY HSC at Syracuse, Inc.
mi
from
Oswego, NY
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Department of Medicine MSG at SUNY HSC at Syracuse, Inc.
mi
from
Oswego, NY
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
SUNY Upstate Medical University
mi
from
Syracuse, NY
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
SUNY Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Department of Medicine MSG at SUNY HSC at Syracuse, Inc.
mi
from
Syracuse, NY
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Department of Medicine MSG at SUNY HSC at Syracuse, Inc.
mi
from
Syracuse, NY
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Raleigh Hematology Oncology Associates
mi
from
Cary, NC
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Raleigh Hematology Oncology Associates
mi
from
Cary, NC
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Investigational Chemotherapy Services
mi
from
Durham, NC
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Investigational Chemotherapy Services
mi
from
Durham, NC
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Albermarie Hospitals
mi
from
Elizabeth City, NC
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Albermarie Hospitals
mi
from
Elizabeth City, NC
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Virginia Oncology Associates
mi
from
Elizabeth City, NC
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Virginia Oncology Associates
mi
from
Elizabeth City, NC
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Raleigh Hematology Oncology Associates
mi
from
Raleigh, NC
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Raleigh Hematology Oncology Associates
mi
from
Raleigh, NC
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Case Western Reserve Univ
mi
from
Cleveland, OH
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
mi
from
Columbus, OH
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
mi
from
Columbus, OH
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
James Care in Kenny
mi
from
Columbus, OH
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
James Care in Kenny
mi
from
Columbus, OH
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Monarch
mi
from
Mayfield Heights, OH
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Monarch
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Lake University - Ireland Cancer Center (LUICC)
mi
from
Mentor, OH
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Lake University - Ireland Cancer Center (LUICC)
mi
from
Mentor, OH
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
UHHS - Chagrin Highlands
mi
from
Orange Village, OH
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
UHHS - Chagrin Highlands
mi
from
Orange Village, OH
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
UHHS - Westlake
mi
from
Westlake, OH
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
UHHS - Westlake
mi
from
Westlake, OH
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Oncology Associates of Oregon, PC
mi
from
Eugene, OR
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Oncology Associates of Oregon, PC
mi
from
Eugene, OR
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Willamette Valley Cancer Institute and Research Center
mi
from
Springfield, OR
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Willamette Valley Cancer Institute and Research Center
mi
from
Springfield, OR
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Cancer Centers of the Carolinas
mi
from
Easley, SC
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Cancer Centers of the Carolinas
mi
from
Easley, SC
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Hematology and Oncology Associates of SC, LLC - Eastside Medical Center
mi
from
Greenville, SC
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Hematology and Oncology Associates of SC, LLC - Eastside Medical Center
mi
from
Greenville, SC
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Cancer Centers of the Carolinas - Seneca
mi
from
Seneca, SC
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Cancer Centers of the Carolinas - Seneca
mi
from
Seneca, SC
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Cancer Centers of the Carolinas
mi
from
Spartanburg, SC
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Cancer Centers of the Carolinas
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Tennessee Oncology, PLLC
mi
from
Franklin, TN
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Tennessee Oncology, PLLC
mi
from
Franklin, TN
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Franklin, TN
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Franklin, TN
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Tennessee Oncology, PLLC
mi
from
Gallatin, TN
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Tennessee Oncology, PLLC
mi
from
Gallatin, TN
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Tennessee Oncology, PLLC
mi
from
Hermitage, TN
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Tennessee Oncology, PLLC
mi
from
Hermitage, TN
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Chattanooga Oncology & Hematology Associates
mi
from
Hixson, TN
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Chattanooga Oncology & Hematology Associates
mi
from
Hixson, TN
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Tennessee Oncology, PLLC
mi
from
Lebanon, TN
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Tennessee Oncology, PLLC
mi
from
Lebanon, TN
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Tennessee Oncology, PLLC
mi
from
Murfreesboro, TN
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Tennessee Oncology, PLLC
mi
from
Murfreesboro, TN
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Tennessee Oncology, PLLC
mi
from
Smyrna, TN
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Tennessee Oncology, PLLC
mi
from
Smyrna, TN
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - Austin Midtown
mi
from
Austin, TX
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Austin Midtown
mi
from
Austin, TX
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - Central Midtown
mi
from
Austin, TX
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Central Midtown
mi
from
Austin, TX
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Texas Oncology-Austin Central
mi
from
Austin, TX
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Texas Oncology-Austin Central
mi
from
Austin, TX
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - South Austin
mi
from
Austin, TX
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - South Austin
mi
from
Austin, TX
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Texas Oncolgoy - Austin North
mi
from
Austin, TX
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Texas Oncolgoy - Austin North
mi
from
Austin, TX
Click here to add this to my saved trials
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, PA - Austin Northwest
mi
from
Austin, TX
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, PA - Austin Northwest
mi
from
Austin, TX
Click here to add this to my saved trials